Johnson & Johnson, one of the largest drugmakers developing a vaccine against COVID-19, has begun the process of applying for emergency approval of its vaccine from the European Medicines Agency and Health Canada.
In what’s called a rolling submission, J&J’s Janssen Pharmaceutical business sent regulators in the EU and Canada early testing data from its experimental one-dose vaccine for preventing COVID-19.
Rolling submissions are used to speed up evaluation of crucial drugs by giving regulators data as it becomes available, and while human testing is still ongoing, rather than submitting reams of data at once after testing ends.
